Jonathan Philip Segal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jonathan Philip Segal has a total of 522 co-authors. Here are the top co-authors by number of shared publications:
- Matthew James Brookes
The Royal Wolverhampton NHS Trust, Wolverhampton, UK
9 shared publications Ailsa L Hart
CSt Mark’s Hospital, Harrow, UK and Imperial College London, London, UK
7 shared publications- Benjamin Harvey Mullish
Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London , London
7 shared publications Omar D Faiz
Department of Inflammatory bowel disease, St. Mark's Hospital, Harrow, United Kingdom
7 shared publications- Shaji Sebastian
IBD Unit, Department of Gastroenterology, Hull University Teaching Hospitals, Hull, UK
7 shared publications Susan K Clark
Department of Inflammatory bowel disease, St. Mark's Hospital, Harrow, United Kingdom
7 shared publications
Latest Publications
- Open Access
Establishing Stakeholder Priorities for Development of a Multi‐Arm Multi‐Stage Platform Trial in Crohn's Disease
Background and Aims: The expanding range of advanced therapies for Crohn's disease (CD) has increased complexity in treatment selection, particularly in refractory disease. Conventional randomised controlled trials are limited in evaluating multiple treatment strategies efficiently. We aimed to establish stakeholder consensus regarding the key clinical priorities required to inform subsequent development of a multi‐arm multi‐stage adaptive platform trial for Crohn's disease. Methods: A two‐stage modified Delphi process was conducted with international stakeholders, including clinicians, trialists, allied health professionals and patients with CD. Delphi 1 identified priority populations, interventions and comparators; Delphi 2 focused on outcomes. Consensus was predefined as ≥ 70% agreement. Results: A total of 112 participants were included in Delphi 1 and 240 in Delphi 2. Patients with exposure to ≥ 2 advanced therapy classes were prioritised as the target population (83%). Multiple advanced therapies across mechanistic classes were selected, with support for inclusion of dual advanced therapy strategies (82%). Standard‐of‐care comparator strategies reflecting real‐world practice were endorsed (83%). Clinical remission was identified as the preferred primary outcome (100%), with support for composite endpoints including endoscopic response at 48 weeks (70%). Objective measures, including endoscopy, imaging and biomarkers, were prioritised, alongside central reading and standardised assessment timepoints. Conclusions: This study established stakeholder consensus on key priorities relating to population selection, interventions, comparator strategies and outcome measures to inform development of a future multi‐arm multi‐stage adaptive platform trial in Crohn's disease. These findings provide an evidence‐informed foundation for subsequent protocol development rather than defining the final trial architecture.
Open AccessEstablishing Stakeholder Priorities for Development of a Multi‐Arm Multi‐Stage Platform Trial in Crohn's Disease
Background and Aims: The expanding range of advanced therapies for Crohn's disease (CD) has increased complexity in treatment selection, particularly in refractory disease. Conventional randomised controlled trials are limited in evaluating multiple treatment strategies efficiently. We aimed to establish stakeholder consensus regarding the key clinical priorities required to inform subsequent development of a multi‐arm multi‐stage adaptive platform trial for Crohn's disease. Methods: A two‐stage modified Delphi process was conducted with international stakeholders, including clinicians, trialists, allied health professionals and patients with CD. Delphi 1 identified priority populations, interventions and comparators; Delphi 2 focused on outcomes. Consensus was predefined as ≥ 70% agreement. Results: A total of 112 participants were included in Delphi 1 and 240 in Delphi 2. Patients with exposure to ≥ 2 advanced therapy classes were prioritised as the target population (83%). Multiple advanced therapies across mechanistic classes were selected, with support for inclusion of dual advanced therapy strategies (82%). Standard‐of‐care comparator strategies reflecting real‐world practice were endorsed (83%). Clinical remission was identified as the preferred primary outcome (100%), with support for composite endpoints including endoscopic response at 48 weeks (70%). Objective measures, including endoscopy, imaging and biomarkers, were prioritised, alongside central reading and standardised assessment timepoints. Conclusions: This study established stakeholder consensus on key priorities relating to population selection, interventions, comparator strategies and outcome measures to inform development of a future multi‐arm multi‐stage adaptive platform trial in Crohn's disease. These findings provide an evidence‐informed foundation for subsequent protocol development rather than defining the final trial architecture.
- 16 August 2026
- Published by Wiley in Internal Medicine Journal
Dose escalation for secondary loss of response in inflammatory bowel disease: 3‐year outcomes and treatment persistence
Background: Dose escalation of biologic therapies is commonly used to manage secondary loss of response in inflammatory bowel disease, although long‐term real‐world outcomes remain limited. Aims: To evaluate long‐term clinical outcomes and treatment persistence following biologic dose escalation for secondary loss of response in inflammatory bowel disease. Methods: We conducted a retrospective cohort study of patients with inflammatory bowel disease who underwent dose escalation of infliximab, adalimumab or vedolizumab at a tertiary referral centre between 2018 and 2024. Outcomes included clinical disease activity scores, biochemical markers and treatment persistence, assessed at 3–12 months and annually up to 36 months following escalation. Results: A total of 155 patients were included (median age 31 years; 46% female), of whom 76% had Crohn's disease. A total of 89 patients received infliximab, 48 adalimumab and 18 vedolizumab. Dose escalation was undertaken for secondary loss of response in 68% and low drug concentrations in 42%. Infliximab escalation was associated with improvement in disease activity scores at 3 months, sustained to 36 months, with reductions in C‐reactive protein across follow‐up. Adalimumab escalation improved Harvey–Bradshaw Index at 3, 12 and 24 months, with reduction in faecal calprotectin at 3 months. Vedolizumab escalation improved Simple Clinical Colitis Activity Index at 3 months only. Treatment persistence at 36 months was 58% for infliximab, 65% for adalimumab and 73% for vedolizumab. Nine patients experienced minor adverse events. Conclusions: Biologic dose escalation was associated with improvement in disease activity and modest treatment persistence following secondary loss of response in inflammatory bowel disease.
- 16 August 2026
- Published by Wiley in Internal Medicine Journal
Dose escalation for secondary loss of response in inflammatory bowel disease: 3‐year outcomes and treatment persistence
Background: Dose escalation of biologic therapies is commonly used to manage secondary loss of response in inflammatory bowel disease, although long‐term real‐world outcomes remain limited. Aims: To evaluate long‐term clinical outcomes and treatment persistence following biologic dose escalation for secondary loss of response in inflammatory bowel disease. Methods: We conducted a retrospective cohort study of patients with inflammatory bowel disease who underwent dose escalation of infliximab, adalimumab or vedolizumab at a tertiary referral centre between 2018 and 2024. Outcomes included clinical disease activity scores, biochemical markers and treatment persistence, assessed at 3–12 months and annually up to 36 months following escalation. Results: A total of 155 patients were included (median age 31 years; 46% female), of whom 76% had Crohn's disease. A total of 89 patients received infliximab, 48 adalimumab and 18 vedolizumab. Dose escalation was undertaken for secondary loss of response in 68% and low drug concentrations in 42%. Infliximab escalation was associated with improvement in disease activity scores at 3 months, sustained to 36 months, with reductions in C‐reactive protein across follow‐up. Adalimumab escalation improved Harvey–Bradshaw Index at 3, 12 and 24 months, with reduction in faecal calprotectin at 3 months. Vedolizumab escalation improved Simple Clinical Colitis Activity Index at 3 months only. Treatment persistence at 36 months was 58% for infliximab, 65% for adalimumab and 73% for vedolizumab. Nine patients experienced minor adverse events. Conclusions: Biologic dose escalation was associated with improvement in disease activity and modest treatment persistence following secondary loss of response in inflammatory bowel disease.
- 15 July 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Sensitivity and specificity of diagnostic modalities to diagnose CMV in coexisting IBD in patients hospitalized with acute colitis: a systematic review and meta-analysis.
Cytomegalovirus (CMV), a common infection, can reactivate and cause CMV-associated colitis in immunosuppressed people, like those with known inflammatory bowel disease (IBD). Diagnosis of CMV colitis is limited by the broad spectrum of CMV infection and the invasiveness of biopsy-based investigations. We aimed to generate diagnostic accuracy estimates for serum, stool, and tissue polymerase chain reaction (PCR), pp65 antigenemia, and hematoxylin and eosin (H&E) staining in diagnosing CMV colitis in IBD patients hospitalized with acute colitis. We systematically searched the MEDLINE and EMBASE databases via OVID from inception until March 3, 2025, for eligible studies for a meta-analysis. Included studies needed to compare 2 tests and report true positives, false negatives, false positives, and true negatives to enable sensitivity and specificity calculations. In total, 23 studies were included. Tissue PCR had the highest log diagnostic odds ratio at 2.93, with a pooled sensitivity of 95% and pooled specificity of 66%. The remaining pooled sensitivity and specificity, respectively, were stool PCR 70% and 92%, serum PCR 61% and 91%, pp65 antigenemia 33% and 98%, and H&E 44% and 99%. Tissue PCR had the best performance and was the most sensitive marker of CMV colitis in IBD, albeit with poor specificity. Stool PCR is a promising test, but further diagnostic studies are needed. Serum PCR, pp65 antigenemia, and H&E, when positive, seem to be useful in confirming CMV colitis. There is a need for further studies to develop an optimal PCR cutoff to differentiate low-level CMV reactivation from true CMV colitis on PCR testing, which may enhance the diagnostic yield from an endoscopic biopsy that tests both tissue PCR and IHC given the higher sensitivity of tissue PCR.
- 15 July 2026
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
Sensitivity and specificity of diagnostic modalities to diagnose CMV in coexisting IBD in patients hospitalized with acute colitis: a systematic review and meta-analysis.
Cytomegalovirus (CMV), a common infection, can reactivate and cause CMV-associated colitis in immunosuppressed people, like those with known inflammatory bowel disease (IBD). Diagnosis of CMV colitis is limited by the broad spectrum of CMV infection and the invasiveness of biopsy-based investigations. We aimed to generate diagnostic accuracy estimates for serum, stool, and tissue polymerase chain reaction (PCR), pp65 antigenemia, and hematoxylin and eosin (H&E) staining in diagnosing CMV colitis in IBD patients hospitalized with acute colitis. We systematically searched the MEDLINE and EMBASE databases via OVID from inception until March 3, 2025, for eligible studies for a meta-analysis. Included studies needed to compare 2 tests and report true positives, false negatives, false positives, and true negatives to enable sensitivity and specificity calculations. In total, 23 studies were included. Tissue PCR had the highest log diagnostic odds ratio at 2.93, with a pooled sensitivity of 95% and pooled specificity of 66%. The remaining pooled sensitivity and specificity, respectively, were stool PCR 70% and 92%, serum PCR 61% and 91%, pp65 antigenemia 33% and 98%, and H&E 44% and 99%. Tissue PCR had the best performance and was the most sensitive marker of CMV colitis in IBD, albeit with poor specificity. Stool PCR is a promising test, but further diagnostic studies are needed. Serum PCR, pp65 antigenemia, and H&E, when positive, seem to be useful in confirming CMV colitis. There is a need for further studies to develop an optimal PCR cutoff to differentiate low-level CMV reactivation from true CMV colitis on PCR testing, which may enhance the diagnostic yield from an endoscopic biopsy that tests both tissue PCR and IHC given the higher sensitivity of tissue PCR.
- Open Access
Dietary Management After Ulcerative Colitis Surgery: A Thematic Analysis of TikTok Content
Background/Objectives: For patients with Ulcerative Colitis (UC) requiring surgical treatment, post-operative dietary management can pose significant challenges. TikTok is emerging as a popular social media platform for dissemination of health and nutrition information. The aim of this study is to analyse patient-generated content on TikTok regarding dietary management post-UC surgery, in order to identify recurring themes and highlight patient priorities. Methods: Relevant TikTok videos were identified through a systematic search. Search terms were developed by combining ‘diet UC’ or ‘nutrition UC’ with common UC surgical procedures. From each search term, the first 10 videos were screened. If a search produced fewer than 10 results, all identified videos were retrieved. Inclusion criteria were videos in English, and a strong indication that the content creator was diagnosed with UC and had undergone relevant surgery, and was providing nutrition recommendations. Thematic analysis of video transcripts was conducted using Braun and Clarke’s framework to identify common themes. Results: A total of 89 videos, created between 2021 and 2024, were found on the initial search, of which 12 duplicates were removed, and 77 videos were screened. Sixteen English language videos met the inclusion criteria and were analysed. Thematic analysis identified three overarching themes: (1) adaptive dietary progression in the post-surgical period, where patients described a phased approach to reintroducing foods post-surgery; (2) personalisation of diet, highlighting individualised strategies for symptom and hydration management; and (3) Emotional and social impact of dietary restrictions and modifications, including fear of food and social isolation. Conclusions: This thematic analysis offers an insight into how patients navigate the complex management of diet following UC surgery. It is important for clinicians to discuss the dietary information and online content patients are exposed to in relation to their condition. Additionally, clinical practice should evolve to embrace patient-centred, multidisciplinary approaches that validate lived experience, ensure consistent dietary guidance, and address the psychological burden of dietary restriction.
Open AccessDietary Management After Ulcerative Colitis Surgery: A Thematic Analysis of TikTok Content
Background/Objectives: For patients with Ulcerative Colitis (UC) requiring surgical treatment, post-operative dietary management can pose significant challenges. TikTok is emerging as a popular social media platform for dissemination of health and nutrition information. The aim of this study is to analyse patient-generated content on TikTok regarding dietary management post-UC surgery, in order to identify recurring themes and highlight patient priorities. Methods: Relevant TikTok videos were identified through a systematic search. Search terms were developed by combining ‘diet UC’ or ‘nutrition UC’ with common UC surgical procedures. From each search term, the first 10 videos were screened. If a search produced fewer than 10 results, all identified videos were retrieved. Inclusion criteria were videos in English, and a strong indication that the content creator was diagnosed with UC and had undergone relevant surgery, and was providing nutrition recommendations. Thematic analysis of video transcripts was conducted using Braun and Clarke’s framework to identify common themes. Results: A total of 89 videos, created between 2021 and 2024, were found on the initial search, of which 12 duplicates were removed, and 77 videos were screened. Sixteen English language videos met the inclusion criteria and were analysed. Thematic analysis identified three overarching themes: (1) adaptive dietary progression in the post-surgical period, where patients described a phased approach to reintroducing foods post-surgery; (2) personalisation of diet, highlighting individualised strategies for symptom and hydration management; and (3) Emotional and social impact of dietary restrictions and modifications, including fear of food and social isolation. Conclusions: This thematic analysis offers an insight into how patients navigate the complex management of diet following UC surgery. It is important for clinicians to discuss the dietary information and online content patients are exposed to in relation to their condition. Additionally, clinical practice should evolve to embrace patient-centred, multidisciplinary approaches that validate lived experience, ensure consistent dietary guidance, and address the psychological burden of dietary restriction.
- Open Access
- 18 March 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (9) , 1336-1337
Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis
- 18 March 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (9) , 1336-1337
Open AccessLetter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis
- 1 September 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (1) , 167-168
Letter: The Complexity of Deciphering Complex Mechanisms That Underpin Changing Trends in Complex Disease
- 1 September 2025
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (1) , 167-168
Letter: The Complexity of Deciphering Complex Mechanisms That Underpin Changing Trends in Complex Disease
- Open Access
- 1 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1870
Long-Term Outcomes of First-Line Anti-TNF Therapy for Chronic Inflammatory Pouch Conditions: A Multi-Centre Multi-National Study
Background/Objectives: Anti-tumour necrosis factor (anti-TNF) medications were historically commonly prescribed as the first-line biologic treatment for chronic inflammatory pouch conditions. However, their use in these conditions is mainly based on retrospective studies of relatively small numbers of patients with short follow up periods. We aimed to describe the long-term outcomes of first-line anti-TNF therapy in a large, multi-centre, multi-national patient cohort with chronic inflammatory pouch conditions. Methods: This was an observational, retrospective, multi-centre, multi-national study. We included patients with chronic inflammatory pouch conditions initially treated with anti-TNF drugs infliximab (IFX) or adalimumab (ADA), who had a follow up of at least 1 year. The primary outcome was anti-TNF treatment persistence, defined as continuation of anti-TNF throughout the study period. The secondary outcome was pouch failure, defined by the need for a defunctioning ileostomy or pouch excision. Results: We recruited 98 patients with chronic inflammatory pouch conditions initially treated with anti-TNF medications—63 (64.3%) treated with IFX and 35 (35.7%) treated with ADA. Average follow up length was 94.2 months (±54.5). At the end of the study period only 22/98 (22.4%) patients were still on anti-TNF treatment. In those in whom the first-line anti-TNF was discontinued, the median time to discontinuation was 12.2 months (range 5.1–26.9 months). The most common cause for anti-TNF discontinuation was lack of efficacy despite adequate serum drug levels and absence of anti-drug antibody formation (30 patients, 30.6%). Loss of response due to anti-drug antibody formation was the cause for discontinuation in 18 patients (18.4%), while 12 patients (12.2%) stopped treatment because of adverse events or safety concerns. Out of the 76 patients discontinuing anti-TNF treatment, 34 (34.7% of the cohort) developed pouch failure, and 42 (42.8% of the cohort) are currently treated with a different medical therapy. Conclusions: First-line anti-TNF therapy for chronic pouch inflammatory conditions is associated with low long-term persistence rates. This is due to a combination of lack of efficacy and adverse events. A significant percentage of patients initially treated with anti-TNF therapy develop pouch failure.
- 1 August 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (8) , 1870
Open AccessLong-Term Outcomes of First-Line Anti-TNF Therapy for Chronic Inflammatory Pouch Conditions: A Multi-Centre Multi-National Study
Background/Objectives: Anti-tumour necrosis factor (anti-TNF) medications were historically commonly prescribed as the first-line biologic treatment for chronic inflammatory pouch conditions. However, their use in these conditions is mainly based on retrospective studies of relatively small numbers of patients with short follow up periods. We aimed to describe the long-term outcomes of first-line anti-TNF therapy in a large, multi-centre, multi-national patient cohort with chronic inflammatory pouch conditions. Methods: This was an observational, retrospective, multi-centre, multi-national study. We included patients with chronic inflammatory pouch conditions initially treated with anti-TNF drugs infliximab (IFX) or adalimumab (ADA), who had a follow up of at least 1 year. The primary outcome was anti-TNF treatment persistence, defined as continuation of anti-TNF throughout the study period. The secondary outcome was pouch failure, defined by the need for a defunctioning ileostomy or pouch excision. Results: We recruited 98 patients with chronic inflammatory pouch conditions initially treated with anti-TNF medications—63 (64.3%) treated with IFX and 35 (35.7%) treated with ADA. Average follow up length was 94.2 months (±54.5). At the end of the study period only 22/98 (22.4%) patients were still on anti-TNF treatment. In those in whom the first-line anti-TNF was discontinued, the median time to discontinuation was 12.2 months (range 5.1–26.9 months). The most common cause for anti-TNF discontinuation was lack of efficacy despite adequate serum drug levels and absence of anti-drug antibody formation (30 patients, 30.6%). Loss of response due to anti-drug antibody formation was the cause for discontinuation in 18 patients (18.4%), while 12 patients (12.2%) stopped treatment because of adverse events or safety concerns. Out of the 76 patients discontinuing anti-TNF treatment, 34 (34.7% of the cohort) developed pouch failure, and 42 (42.8% of the cohort) are currently treated with a different medical therapy. Conclusions: First-line anti-TNF therapy for chronic pouch inflammatory conditions is associated with low long-term persistence rates. This is due to a combination of lack of efficacy and adverse events. A significant percentage of patients initially treated with anti-TNF therapy develop pouch failure.
- Open Access
- 30 July 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (3) , 347-357
Upadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study
Background/Aims: Upadacitinib is a novel selective Janus kinase inhibitor approved for use in ulcerative colitis. Clinical trials had rigorous criteria and excluded many patient subgroups. Given limited real-world effectiveness data, we examined outcomes of patients treated with upadacitinib for ulcerative colitis in a real-world population. Methods: Patients that commenced upadacitinib for moderate-to-severe ulcerative colitis from September 2022 until March 2023 were identified at 13 inflammatory bowel disease centers across Australia. Clinical, biochemical, endoscopic, and intestinal ultrasound outcomes were recorded retrospectively at baseline, week 8, and week 16. Results: One hundred and fifty-two patients (61 female [40%], median age 38 years [interquartile range, 28–50]) were included. The primary endpoint of clinical remission was met in 79% at week 8, and 84% at week 16. A total of 42 patients (28%) with prior tofacitinib exposure were included. No significant difference in clinical remission was observed by week 16 between tofacitinib experienced compared to tofacitinib naïve patients (86% vs. 84%, P= 0.67). Complete intestinal ultrasound data was available for 36 patients, showing transmural remission in 64% at week 8 and 81% at week 16, with a decrease in median bowel wall thickness of 2.3 mm and 2.4 mm, respectively. Conclusions: Upadacitinib resulted in high rates of clinical remission at 8 and 16 weeks in this large real-world cohort of ulcerative colitis patients. Upadacitinib is effective in patients with prior tofacitinib exposure. Intestinal ultrasound shows significant rates of transmural remission at week 8, sustained through week 16.
- 30 July 2025
- Published by Korean Association for the Study of Intestinal Diseases in Intestinal Research
- Vol. 23 (3) , 347-357
Open AccessUpadacitinib induction is effective and safe in ulcerative colitis patients including those with prior exposure to tofacitinib: a multicenter real-world cohort study
Background/Aims: Upadacitinib is a novel selective Janus kinase inhibitor approved for use in ulcerative colitis. Clinical trials had rigorous criteria and excluded many patient subgroups. Given limited real-world effectiveness data, we examined outcomes of patients treated with upadacitinib for ulcerative colitis in a real-world population. Methods: Patients that commenced upadacitinib for moderate-to-severe ulcerative colitis from September 2022 until March 2023 were identified at 13 inflammatory bowel disease centers across Australia. Clinical, biochemical, endoscopic, and intestinal ultrasound outcomes were recorded retrospectively at baseline, week 8, and week 16. Results: One hundred and fifty-two patients (61 female [40%], median age 38 years [interquartile range, 28–50]) were included. The primary endpoint of clinical remission was met in 79% at week 8, and 84% at week 16. A total of 42 patients (28%) with prior tofacitinib exposure were included. No significant difference in clinical remission was observed by week 16 between tofacitinib experienced compared to tofacitinib naïve patients (86% vs. 84%, P= 0.67). Complete intestinal ultrasound data was available for 36 patients, showing transmural remission in 64% at week 8 and 81% at week 16, with a decrease in median bowel wall thickness of 2.3 mm and 2.4 mm, respectively. Conclusions: Upadacitinib resulted in high rates of clinical remission at 8 and 16 weeks in this large real-world cohort of ulcerative colitis patients. Upadacitinib is effective in patients with prior tofacitinib exposure. Intestinal ultrasound shows significant rates of transmural remission at week 8, sustained through week 16.